[Antitumor effect of S-1 and cisplatin treatment against human gastric cancer xenografted in nude mice].
The enhanced effects due to the combined use of oral administration of S-1 and intraperitoneal administration of Cisplatin (CDDP) were examined with gastric cancer xenografts (NUGC 4). S-1, a new anticancer drug, was daily administered at 10 mg/kg (qld x 5 x 3 weeks). 5-FU level in blood was 1 microgram/ml at two hours after the treatment. Antitumor activity was not found in mice with only the CDDP treatment. But antitumor activity by S-1 and daily low-dose (1 mg/kg) or intermittent treatment (5 mg/kg) of CDDP showed better results than daily S-1 treatment. The daily low-dose CDDP treatment showed similar efficacy to the intermittent administration at the same total dose, but the daily low-dose CDDP treatment was better in the light of toxicities. These results suggest that treatment with S-1 and daily low-dose CDDP was effective for gastric cancer.
Kondo
K
K
Dept. of Surgery II, Nagoya University School of Medicine.
Akiyama
S
S
Kasai
Y
Y
Kato
S
S
Kuno
Y
Y
Kataoka
M
M
Ichihara
T
T
Horisawa
M
M
Shirasaka
T
T
D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006801:Humans; D007263:Infusions, Parenteral; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011725:Pyridines / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000188:drug therapy*; D014183:Transplantation, Heterologous
D011725:Pyridines; D002945:Cisplatin; C104201:gimeracil